Effect of fraxiparine and heparin on experimental tumor metastasis in mice

B. Szende, S. Paku, Gergely Rácz, L. Kópper

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Low molecular weight heparins (LMWH) have become increasingly important in anticoagulant therapy. Antitumor and antimetastatic activity of heparin and LMWH-s have also been reported. Materials and Methods: Fraxiparine, a new modified LMW-H, was tested for antimetastatic effect using 3LL-HH intravenous, B16 intra-foot pad and 3LL-HH intrasplenic models in C57 Bl/6 mice. The dose of Fraxiparine was 38, 57 and 172 IU/kg, respectively. Heparin (100 IU/kg) was used as a positive control. Both pre-treatment (starting 6 hours before tumor inoculation) and post-treatment (starting 24 hours after tumor inoculation), followed by daily injections, were applied in the intra-foot pad and intrasplenic models. In the intravenous model, only a single dose was administered one hour after tumor cell injection. Results: Fraxiparine at the dose of 57 IU/kg was significantly antimetastatic in the intravenous model. Continuous treatment, starting 6 hours before tumor inoculation, with 173 IU/kg Fraxiparine resulted in a strong inhibition of lung metastases in the intra-foot pad model, but was ineffective in the intrasplenic model. Heparin did not influence the metastasis number in any of the metastasis models. Conclusion: These data may be of importance in the anticoagulant treatment of human cancer patients.

Original languageEnglish
Pages (from-to)2869-2872
Number of pages4
JournalAnticancer Research
Volume25
Issue number4
Publication statusPublished - Jul 2005

Fingerprint

Nadroparin
Heparin
Neoplasm Metastasis
Foot
Low Molecular Weight Heparin
Neoplasms
Anticoagulants
Therapeutics
Injections
Lung

Keywords

  • Fraxiparine
  • Heparin
  • Metastasis
  • Mouse
  • Tumors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effect of fraxiparine and heparin on experimental tumor metastasis in mice. / Szende, B.; Paku, S.; Rácz, Gergely; Kópper, L.

In: Anticancer Research, Vol. 25, No. 4, 07.2005, p. 2869-2872.

Research output: Contribution to journalArticle

@article{ab98637a4c404597898ece617eb1b729,
title = "Effect of fraxiparine and heparin on experimental tumor metastasis in mice",
abstract = "Background: Low molecular weight heparins (LMWH) have become increasingly important in anticoagulant therapy. Antitumor and antimetastatic activity of heparin and LMWH-s have also been reported. Materials and Methods: Fraxiparine, a new modified LMW-H, was tested for antimetastatic effect using 3LL-HH intravenous, B16 intra-foot pad and 3LL-HH intrasplenic models in C57 Bl/6 mice. The dose of Fraxiparine was 38, 57 and 172 IU/kg, respectively. Heparin (100 IU/kg) was used as a positive control. Both pre-treatment (starting 6 hours before tumor inoculation) and post-treatment (starting 24 hours after tumor inoculation), followed by daily injections, were applied in the intra-foot pad and intrasplenic models. In the intravenous model, only a single dose was administered one hour after tumor cell injection. Results: Fraxiparine at the dose of 57 IU/kg was significantly antimetastatic in the intravenous model. Continuous treatment, starting 6 hours before tumor inoculation, with 173 IU/kg Fraxiparine resulted in a strong inhibition of lung metastases in the intra-foot pad model, but was ineffective in the intrasplenic model. Heparin did not influence the metastasis number in any of the metastasis models. Conclusion: These data may be of importance in the anticoagulant treatment of human cancer patients.",
keywords = "Fraxiparine, Heparin, Metastasis, Mouse, Tumors",
author = "B. Szende and S. Paku and Gergely R{\'a}cz and L. K{\'o}pper",
year = "2005",
month = "7",
language = "English",
volume = "25",
pages = "2869--2872",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Effect of fraxiparine and heparin on experimental tumor metastasis in mice

AU - Szende, B.

AU - Paku, S.

AU - Rácz, Gergely

AU - Kópper, L.

PY - 2005/7

Y1 - 2005/7

N2 - Background: Low molecular weight heparins (LMWH) have become increasingly important in anticoagulant therapy. Antitumor and antimetastatic activity of heparin and LMWH-s have also been reported. Materials and Methods: Fraxiparine, a new modified LMW-H, was tested for antimetastatic effect using 3LL-HH intravenous, B16 intra-foot pad and 3LL-HH intrasplenic models in C57 Bl/6 mice. The dose of Fraxiparine was 38, 57 and 172 IU/kg, respectively. Heparin (100 IU/kg) was used as a positive control. Both pre-treatment (starting 6 hours before tumor inoculation) and post-treatment (starting 24 hours after tumor inoculation), followed by daily injections, were applied in the intra-foot pad and intrasplenic models. In the intravenous model, only a single dose was administered one hour after tumor cell injection. Results: Fraxiparine at the dose of 57 IU/kg was significantly antimetastatic in the intravenous model. Continuous treatment, starting 6 hours before tumor inoculation, with 173 IU/kg Fraxiparine resulted in a strong inhibition of lung metastases in the intra-foot pad model, but was ineffective in the intrasplenic model. Heparin did not influence the metastasis number in any of the metastasis models. Conclusion: These data may be of importance in the anticoagulant treatment of human cancer patients.

AB - Background: Low molecular weight heparins (LMWH) have become increasingly important in anticoagulant therapy. Antitumor and antimetastatic activity of heparin and LMWH-s have also been reported. Materials and Methods: Fraxiparine, a new modified LMW-H, was tested for antimetastatic effect using 3LL-HH intravenous, B16 intra-foot pad and 3LL-HH intrasplenic models in C57 Bl/6 mice. The dose of Fraxiparine was 38, 57 and 172 IU/kg, respectively. Heparin (100 IU/kg) was used as a positive control. Both pre-treatment (starting 6 hours before tumor inoculation) and post-treatment (starting 24 hours after tumor inoculation), followed by daily injections, were applied in the intra-foot pad and intrasplenic models. In the intravenous model, only a single dose was administered one hour after tumor cell injection. Results: Fraxiparine at the dose of 57 IU/kg was significantly antimetastatic in the intravenous model. Continuous treatment, starting 6 hours before tumor inoculation, with 173 IU/kg Fraxiparine resulted in a strong inhibition of lung metastases in the intra-foot pad model, but was ineffective in the intrasplenic model. Heparin did not influence the metastasis number in any of the metastasis models. Conclusion: These data may be of importance in the anticoagulant treatment of human cancer patients.

KW - Fraxiparine

KW - Heparin

KW - Metastasis

KW - Mouse

KW - Tumors

UR - http://www.scopus.com/inward/record.url?scp=22944447451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22944447451&partnerID=8YFLogxK

M3 - Article

C2 - 16080539

AN - SCOPUS:22944447451

VL - 25

SP - 2869

EP - 2872

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -